Related Experiment Video
Updated: Mar 14, 2026
10:21
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
10.7K
Potential Markers in Cardiac Hypertrophy?
Bartosz Malinowski1, Gabriele Fulgheri2, Michal Wicinski3
1Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland; Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
EJIFCC
|September 30, 2016
Summary
Emerging biomarkers like osteopontin and ST-2 receptor show promise for diagnosing cardiomyopathies. This review explores novel biochemical tests to complement traditional methods in cardiology research.
Area of Science:
- Cardiology
- Biochemistry
- Biomarker Discovery
Background:
- Cardiomyopathies are diagnosed using medical history, physical exams, and imaging like echocardiograms.
- Current non-invasive diagnostic methods for cardiomyopathies can be enhanced by biochemical tests.
Purpose of the Study:
- To review emerging potential biomarkers for cardiomyopathy diagnosis.
- To explore novel biochemical markers that can complement existing diagnostic tools.
Main Methods:
- Review of human and non-human investigations.
- Focus on experimental cardiology models, particularly the rat model.
Main Results:
- Description of emerging biomarkers including osteopontin, ST-2 receptor, osteoprotegerin, neopterin, urocortins, growth differentiation factor 15, and urotensin II.
- Highlighting the value of animal models in advancing clinical knowledge.
Conclusions:
- Novel biomarkers offer potential to improve cardiomyopathy diagnosis.
- Biochemical tests can serve as valuable additions to current diagnostic strategies in cardiology.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
611
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
611
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
1.1K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
684
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
684
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
705
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
705
01:17Pathophysiology of Heart Failure
4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K